Lecanemab, sold under the brand name Leqembi, is a prescription medicine that targets a protein called beta-amyloid in the brain. It is used to treat early Alzheimer's disease and can slow the average rate of memory and thinking decline. It does not cure Alzheimer's or restore abilities that have already been lost.
What does lecanemab mean in simple terms?
Lecanemab is a type of medicine called an anti-amyloid monoclonal antibody. This means it is a specially designed protein that recognizes and attaches to certain forms of beta-amyloid, a protein associated with Alzheimer's disease.
In Alzheimer's disease, beta-amyloid can collect in the brain and form clumps called amyloid plaques. These plaques are one of the important changes seen in the brains of people with the disease.
Lecanemab attaches to aggregated forms of beta-amyloid and helps reduce the amount of amyloid plaque in the brain. Its purpose is to act on an underlying feature of Alzheimer's disease rather than simply provide temporary relief from memory-related symptoms.
According to the current LEQEMBI prescribing information published by the National Library of Medicine, lecanemab is an antibody directed against aggregated soluble and insoluble forms of amyloid beta.
What is lecanemab used for?
Lecanemab is intended for people in the early stages of Alzheimer's disease. The treatment was studied in adults with either:
- Mild cognitive impairment due to Alzheimer's disease: Changes in memory or thinking are noticeable, but the person can generally continue to manage most everyday activities independently.
- Mild Alzheimer's dementia: Memory and thinking difficulties have begun to interfere with everyday activities and independence.
There is an important requirement: the person must also have evidence of amyloid buildup in the brain. Memory difficulties alone are not enough to establish that someone is a suitable candidate.
The Alzheimer's Association guidance on lecanemab explains that the treatment is intended for early Alzheimer's disease with confirmed beta-amyloid buildup. It has not been established as a treatment for people without cognitive symptoms or those with more advanced Alzheimer's disease.
How does lecanemab work in the brain?
Lecanemab works by recognizing and attaching to beta-amyloid protein deposits. This allows the body to reduce the accumulation of amyloid plaques in the brain.
Reducing these plaques may help slow some of the changes associated with Alzheimer's disease. However, removing amyloid does not reverse all the damage that has already occurred in the brain.
This is why lecanemab is described as a disease-modifying treatment. A disease-modifying medicine acts on an underlying disease process and may change how quickly the condition progresses. It is different from a medicine that primarily helps manage symptoms.
Does lecanemab slow the progression of Alzheimer's?
Clinical research has found that lecanemab can slow cognitive and functional decline in some people with early Alzheimer's disease. Cognitive decline refers to worsening memory, thinking, and other mental abilities. Functional decline means increasing difficulty with everyday activities.
In the large phase 3 CLARITY AD clinical trial, researchers studied 1,795 adults with early Alzheimer's disease over 18 months. Participants receiving lecanemab experienced less decline on average than those receiving a placebo, a treatment without the active medicine.
However, the treatment did not stop the disease from progressing. Both groups experienced some decline, although the average decline was smaller among participants receiving lecanemab.
The New England Journal of Medicine clinical trial report, available through PubMed, describes these findings. The results show a slowing of decline rather than an improvement that restores lost memory or thinking abilities.
How is lecanemab given?
Lecanemab is a prescription treatment administered on a regular schedule under medical supervision. The available method and dosing schedule depend on the approved formulation and treatment plan.
In the current United States prescribing information, lecanemab can be administered in two ways:
- Intravenous infusion: The medicine is given directly into a vein. The initial treatment schedule is generally once every two weeks.
- Subcutaneous injection: The medicine is injected under the skin using a prefilled injection device. The current United States starting schedule is once a week.
After an initial treatment period, the prescribing information also describes maintenance dosing options. The healthcare team determines the appropriate schedule based on the treatment stage and the person's circumstances.
These administration options reflect the current United States product information. Approved formulations and treatment schedules may differ between countries.
Who can be considered for lecanemab treatment?
Lecanemab is not suitable for everyone with memory problems or a diagnosis of dementia. Before considering treatment, a healthcare professional needs to assess whether the person meets the medical requirements.
The assessment generally includes:
- A clinical evaluation of memory, thinking abilities, and everyday functioning.
- Evidence that Alzheimer's disease is responsible for the cognitive changes.
- A test confirming beta-amyloid buildup, such as an amyloid PET scan or a cerebrospinal fluid test.
- A brain MRI to check for existing abnormalities that could affect treatment safety.
- A review of medical history and other medicines, particularly those that may affect bleeding risk.
Genetic testing may also be discussed before treatment. People who have two copies of the APOE ε4 gene variant have a higher risk of certain serious side effects associated with lecanemab. The current United States prescribing information recommends testing for APOE ε4 status before starting treatment so that this risk can be discussed.
What are the important risks of lecanemab?
Although lecanemab may slow Alzheimer's progression, it can cause side effects. One of the most important safety concerns is a group of changes called amyloid-related imaging abnormalities (ARIA).
ARIA refers to changes in the brain that can be detected using MRI scans. These changes mainly involve:
- ARIA-E: Swelling or fluid buildup in areas of the brain.
- ARIA-H: Small areas of bleeding or blood-related deposits in the brain.
ARIA often does not cause noticeable symptoms and may be found during routine MRI monitoring. However, serious cases can occur and may be life-threatening. This is why brain imaging and careful clinical supervision are essential during treatment.
Other commonly reported side effects include:
- Headache.
- Reactions during or after an infusion.
- Swelling or bleeding-related changes detected on MRI.
- Injection-site reactions with the subcutaneous formulation.
The Mayo Clinic overview of lecanemab also explains that some people require treatment interruption or additional medical care because of side effects.
Why are regular MRI scans needed during treatment?
Brain MRI scans help healthcare professionals identify ARIA, including swelling and small areas of bleeding that may not cause symptoms.
A brain MRI is required before starting treatment to establish a baseline. Additional scans are performed during treatment to look for new changes and help the healthcare team decide whether treatment can continue safely.
The frequency of monitoring follows the prescribing information and may depend on the treatment formulation and individual risk factors. New or unusual neurological symptoms during treatment need prompt medical assessment, even when a recent MRI was normal.
Is lecanemab a cure for Alzheimer's disease?
No. Lecanemab is not a cure for Alzheimer's disease. It is designed to slow the progression of early Alzheimer's by reducing beta-amyloid buildup in the brain.
It does not reverse the disease, restore memories that have already been lost, or guarantee that a person will maintain their current abilities. Its benefit is generally described as a reduction in the average rate of cognitive and functional decline compared with no active treatment.
It is also not a proven way to prevent Alzheimer's in people who have no symptoms. Its established treatment population is adults with early Alzheimer's disease and confirmed amyloid buildup.
What should patients and families understand about lecanemab?
Lecanemab represents an important development in Alzheimer's treatment because it targets a biological feature of the disease rather than focusing only on its symptoms. However, its benefits need to be considered alongside its risks and the practical demands of regular treatment and MRI monitoring.
For patients and families, the most important points are:
- Lecanemab is an anti-amyloid antibody medicine, also known by the brand name Leqembi.
- It is intended for selected adults with early Alzheimer's disease, not all stages of the condition.
- Confirmation of amyloid buildup is needed before treatment begins.
- It may slow memory, thinking, and functional decline, but it does not cure Alzheimer's.
- Brain swelling and bleeding are important potential risks, so regular MRI monitoring is necessary.
A neurologist or other specialist experienced in Alzheimer's disease can explain whether the treatment is appropriate, what benefits may reasonably be expected, and how its risks compare with other available care options.